#AI Solutions #healthcare technology #Netherlands #Amsterdam #SkinVision

SkinVision Pro: A New Era in Skin Health Technology

In a significant development for dermatological health, SkinVision has officially launched SkinVision Pro at the HLTH Europe conference, marking a pivotal moment in the integration of artificial intelligence into healthcare. This innovative platform connects medical practices directly with the SkinVision Service, an AI-driven solution designed to assess the risk of skin spots more efficiently.

Addressing a Growing Need

The urgency for such a platform has never been clearer, given the alarming statistics that indicate skin cancer rates have surged threefold over the last two decades. With dermatological appointments often involving wait times extending up to six months in many healthcare systems, both general practitioners (GPs) and patients are increasingly finding themselves adrift without a cohesive understanding of a patient’s skin health prior to the consultation.

How SkinVision Pro Works

The primary aim of SkinVision Pro is to bridge this gap. Normally, patients arrive at clinics for a consultation without any relevant context about their skin concerns, leaving healthcare providers in the lurch until the appointment starts. With this platform, patients can utilize the SkinVision Service from home to assess specific skin spots. They receive an AI-generated risk indication along with guidance—whether to monitor their condition or seek professional medical advice—before even scheduling an appointment.

Upon their visit, the practice or clinic can access an integrated dashboard that displays the lesion's image, any reported symptoms, and the AI's risk assessment. Importantly, SkinVision takes on the responsibility of addressing any patient inquiries regarding the service, ensuring that the healthcare providers can focus on care without feeling overwhelmed by administrative tasks.

Proven Clinical Effectiveness

Notably, the SkinVision Service has received CE marking as a Class IIa medical device, boasting clinically validated performance with over 90% sensitivity and 89% specificity in skin cancer detection. Initial data gathered from Dutch primary care users during the first quarter of 2026 reveals promising outcomes: 80% of users received a low-risk signal and were reassured without needing an immediate doctor's appointment. Alarmingly, of those flagged with a high-risk indication, 24% were subsequently diagnosed with skin cancer—a statistic that emphasizes the potential impact of timely skin assessments.

Transforming Patient Consultations

Erik de Heus, CEO of SkinVision, articulated the value of this service: “Skin conditions account for around 15% of GP consultations. The SkinVision Pro platform allows healthcare professionals to better engage with their patients’ skin health data right from the start, facilitating a more efficient consulting process.”

Features of the Early Adopter Package

For medical professionals eager to join the SkinVision Pro initiative, the early adopter package offers a comprehensive setup. It includes full access to the SkinVision Pro dashboard, educational resources via the SkinVision Academy, patient onboarding materials, and dedicated customer support to ensure seamless integration into existing practice operations. This thoughtful combination aims to prepare clinics for enhanced patient assessments, ultimately improving the quality of care delivered during consultations.

The early adopter offer can be found at SkinVision Pro.

About SkinVision

Founded in 2012 and headquartered in Amsterdam, SkinVision has established itself as a leader in AI-powered skin health assessments, having facilitated over six million skin checks for more than three million users globally. The SkinVision Service, although not a diagnostic tool for skin cancers, empowers users to record and monitor skin spots of concern, and delivers risk indications warranting further medical evaluation. For more information, visit SkinVision's website.